Autolus Therapeutics plc (6A3A) - Total Assets
Based on the latest financial reports, Autolus Therapeutics plc (6A3A) holds total assets worth €589.07 Million EUR (≈ $688.68 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Autolus Therapeutics plc (6A3A) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Autolus Therapeutics plc - Total Assets Trend (2017–2025)
This chart illustrates how Autolus Therapeutics plc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Autolus Therapeutics plc for net asset value and shareholders' equity analysis.
Autolus Therapeutics plc - Asset Composition Analysis
Current Asset Composition (December 2025)
Autolus Therapeutics plc's total assets of €589.07 Million consist of 74.0% current assets and 26.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 17.7% |
| Accounts Receivable | €24.02 Million | 4.1% |
| Inventory | €33.21 Million | 5.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €19.81 Million | 3.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Autolus Therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Autolus Therapeutics plc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Autolus Therapeutics plc's current assets represent 74.0% of total assets in 2025, a decrease from 95.8% in 2017.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2025, down from 92.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 5.6% of total assets.
Autolus Therapeutics plc Competitors by Total Assets
Key competitors of Autolus Therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Autolus Therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.94 | 10.88 | 9.41 |
| Quick Ratio | 5.48 | 10.81 | 9.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €362.48 Million | €600.19 Million | €257.46 Million |
Autolus Therapeutics plc - Advanced Valuation Insights
This section examines the relationship between Autolus Therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.38 |
| Latest Market Cap to Assets Ratio | 0.61 |
| Asset Growth Rate (YoY) | -24.7% |
| Total Assets | €589.07 Million |
| Market Capitalization | $361.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values Autolus Therapeutics plc's assets below their book value (0.61x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Autolus Therapeutics plc's assets decreased by 24.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Autolus Therapeutics plc (2017–2025)
The table below shows the annual total assets of Autolus Therapeutics plc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €589.07 Million ≈ $688.68 Million |
-24.74% |
| 2024-12-31 | €782.73 Million ≈ $915.09 Million |
+108.51% |
| 2023-12-31 | €375.38 Million ≈ $438.86 Million |
-23.43% |
| 2022-12-31 | €490.27 Million ≈ $573.18 Million |
+20.89% |
| 2021-12-31 | €405.56 Million ≈ $474.14 Million |
+37.83% |
| 2020-12-31 | €294.24 Million ≈ $343.99 Million |
-3.06% |
| 2019-12-31 | €303.53 Million ≈ $354.86 Million |
+11.10% |
| 2018-12-31 | €273.20 Million ≈ $319.41 Million |
+83.78% |
| 2017-12-31 | €148.66 Million ≈ $173.80 Million |
-- |
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more